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ABSTRACT 
 
Background: Hepatitis B virus (HBV) vaccination is recommended for all susceptible 
dialysis patients. Patients on chronic dialysis exhibit diminished seroconversion rates to HBV 
vaccine. Multiple factors have been associated with a favourable response to HBV vaccination 
in hemodialysis (HD) patients; nevertheless, studies with such endpoint concerning peritoneal 
dialysis (PD) patients are sparse. We aimed to find any factors associated with an immune 
response in a PD population. 
Methods: We retrospectively evaluated seroconversion after HBV vaccination in a PD 
population submitted to this vaccine. 
Results: Thirty five end-stage renal disease (ESRD) adult patients on maintenance PD were 
included – 18 patients who completed a primary vaccination series during PD (group V1) and 
17 patients who were submitted to a rechallenge immunization while on PD (group V2). Older 
patients, defined as age superior to 50 years old, had a lower seroconversion rate (52.4% vs. 
92.9%) (p = 0.023). Seroconversion to HBV vaccine was independent from gender, weight, 
body mass index, smoking, diabetes, chronic kidney disease etiology, previous blood 
transfusion, renal transplant, PD modality, PD adequacy, residual renal function, peritoneal 
equilibration test classification, number of peritonitis, time on PD prior to vaccination, albumin 
and haemoglobin levels, recombinant human erythropoietin injection, immunosuppressant 
therapy, vitamin D administration and antidepressants intake. Among responders, hepatitis 
B surface antibody titres of younger patients significantly exceeded those of older patients (p = 
0.01).   
Conclusions: Only older age was significantly associated with an impaired immune response 
to HBV vaccination in ESRD patients on maintenance PD. 
 
KEY WORDS: Peritoneal dialysis; hepatitis B virus; vaccination; seroconversion. 
 
3 
 
INTRODUCTION 
 
End-stage renal disease (ESRD) is associated with a compromised immune defence due to T-
cell dysfunction (1), which increases susceptibility to infectious diseases (2).   
Hepatitis B virus (HBV) infection is an ubiquitous chronic viral infection with considerable 
morbidity and financial burden, and its prevalence in ESRD patients undergoing long-term 
dialysis is not negligible (3, 4). These patients are more prone to become HBV chronic carriers, 
increasing their risk of fulminant hepatitis, chronic liver disease, liver cirrhosis or hepatocellular 
carcinoma (5).  
In order to prevent HBV infection, hygienic precautions must be implemented and the 
Advisory Committee on Immunization Practices recommends hepatitis B vaccination for all 
susceptible dialysis patients. 
Besides greater predisposition to infections, ESRD patients exhibit diminished 
seroconversion rates to vaccines (6); in fact, comparing with the non-uremic population, a lower 
number of patients going through chronic dialysis develops protective serum hepatitis 
B surface antibody (anti-HBs) levels, and even among responders, anti-HBs titres tend to be low 
and decline faster (7). 
There are two major dialysis modalities, hemodialysis (HD) and peritoneal dialysis (PD), 
with equal outcomes regarding quality of life and mortality (8, 9). There are many studies trying 
to find a favourable response to HBV vaccination in HD patients. The factors already associated 
with it are: lower age (4), female gender (3, 10), non-obese (11), non-diabetic (12), absent 
human immunodeficiency virus infection (13) or hepatitis C virus infection (14), increased 
length of time on dialysis prior to receipt of vaccine (15), adequate nutritional status (16), 
treatment with recombinant human erythropoietin (rHuEPO) (17), no history of blood 
transfusion (6) or renal transplant (18), haemoglobin >11g/dL (1) and no depression (19). 
However, there is a lack of information on the seroconversion after HBV vaccination in PD 
patients.  
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In this study we aimed to find any factors associated with an immune response in a PD 
population.  
 
 
METHODS 
 
PATIENTS AND EXCLUSION CRITERIA 
This was a single centre retrospective study performed with ESRD adult patients on 
maintenance PD followed on a routine basis at Centro Hospitalar São João (Porto, Portugal) 
peritoneal dialysis unit at the beginning of January 2017. We excluded patients who were not 
vaccinated for HBV while on PD, and those who were positive for either hepatitis B surface 
antigen or anti-hepatitis B core. Patients were categorized into two groups: (V1) those who 
completed a primary vaccination series; (V2) those who received a rechallenge immunization. 
 
DATA ACQUISITION 
The Ethics Committee of Centro Hospitalar São João approved the study protocol and 
waived the requirement for patient informed consent. The following variables were recorded for 
all patients: age, gender, height, weight, body mass index (BMI), chronic kidney disease (CKD) 
etiology, history of renal transplant, smoking, diabetes and previous blood transfusions; dialysis 
modality (continuous ambulatory PD [CAPD] or automated PD [APD]), dialysis adequacy, 
residual renal function (RRF) and peritoneal equilibration test (PET) classification at the time of 
vaccination; number of peritonitis and length of time on dialysis prior to vaccination; serum 
albumin and haemoglobin levels just before and 1 year after vaccination; anti-HBs titre right 
before initiating and at least 2 months after completing immunization schedule; rHuEPO 
injection and antidepressants, vitamin D or immunosuppressant drugs intake during vaccination.  
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END-POINT OF INTEREST 
Our purpose was to find whether any of the previously mentioned variables were associated 
with HBV vaccine-induced seroprotection in PD patients; those with an anti-HBs titre ≥ 10 IU/L 
were classified as responders – i.e. seroprotected. 
 
STATISTICAL ANALYSIS 
For statistical analysis, SPSS IBM version 25 (IBM Corp., Armonk, NY) was used. We used 
the Fisher’s exact test to identify differences in categorical variables, and the Mann-Whitney 
test to identify differences in numerical variables. Two-tailed p values of less than 0.05 were 
considered statistically significant. 
 
 
RESULTS 
 
We retrospectively collected data from 91 ESRD adult patients on maintenance PD. After 
exclusion of patients who were not vaccinated for HBV while on PD, and who were positive for 
either hepatitis B surface antigen or anti-hepatitis B core, we obtained a total of 35 patients - 18 
patients who completed a primary vaccination series during PD (group V1) and 17 patients who 
were submitted to a rechallenge immunization while on PD (group V2). 
Patients’ characteristics are summarized in table 1. Age ranged from 31 to 82 years old with 
a median of 54 years old, distribution by genre was quite balanced (51% male and 49% female) 
and most were overweight (66%). Hypertension, diabetes or chronic glomerulonephritis 
explained half of the cases of CKD. CAPD was the most frequent dialysis modality (60%) and 
the majority of patients had a satisfactory dialysis adequacy (94%), were given rHuEPO (57%) 
and were classified as high-average or high transporters (88%) according to their PET. Total 
seroconversion rate was 69%. 
Tables 2 and 3 compare responders to non-responders in relation to numerical and 
categorical variables, respectively. Non-responders were statistically significantly older as 
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compared to responders (60 vs. 50 years old; p = 0.014) (table 2). Older patients, defined as age 
superior to 50 years old, had a lower seroconversion rate than younger patients (52% vs. 93%; p 
= 0.023) (figure 1). There were no significant differences between responders and non-
responders with respect to all the remaining variables, namely gender, bodyweight, BMI, 
smoking, diabetes, previous blood transfusion, renal transplant, PD modality, time on PD prior 
to vaccination, PD adequacy, PET classification, RRF, number of peritonitis, haemoglobin or 
albumin levels, and rHuEPO, immunosuppressant, vitamin D or antidepressant therapy. 
Nonetheless, diabetic patients were less likely to respond than non-diabetic (37.5% vs. 77.8%) 
and APD patients exhibited a greater seroconversion rate (85.7%) as compared to CAPD users 
(57.1%); however, neither of these differences were significant (p = 0.077 and p = 0.137, 
respectively). 
Among responders, older patients had statistically significantly inferior anti-HBs titres than 
younger patients (31 vs 451 IU/L; p = 0.01) (figure 2). 
 
 
DISCUSSION 
 
The findings from this study suggest that older PD patients, defined as age superior to fifty 
years old, are less likely to achieve protective anti-HBs titres after vaccination, which is in 
agreement with previous data from multiple studies (4, 20, 21); further, we found that older 
responders exhibit lower anti-HBs levels. Given the consistently lower seroconversion rate and 
anti-HBs titres among older patients, our interpretation of these results is that older age in a PD 
population is significantly associated with an impaired immune response to HBV vaccination. 
Indeed, both immune system dysregulation during ESRD and immunosenescence have been 
linked to insufficient protection following vaccination (2, 22). 
Apart from age, no other factor had a statistically significant effect on immune response to 
HBV vaccine; nonetheless, there was a pronounced trend for diabetes to be negatively 
associated with seroconversion (62.5% non-responders among diabetics compared with 28.6% 
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non-responders among non-diabetics, p = 0.077) which is biologically plausible. In fact, a meta-
analysis by Fabrizi et al. (12) showed that diabetes mellitus is significantly associated with an 
impaired HBV immunoprophylaxis both in HD and CAPD patients. We argue that the absence 
of a statistically significant association between diabetes and immune response may be related 
to insufficient statistical power. 
The National Kidney Foundation guidelines recommend PD adequacy, measured as total 
Kt/V, to be at least 1.7 per week. Studies comparing PD adequacy between responders and non-
responders to HBV vaccine reported inconsistent results: Dervisoglu et al. (23) did not find 
significant differences, whereas Svac et al. (24) found a significant difference in response rate 
between patients with a weekly Kt/V greater than 1.7 and patients with a weekly Kt/V below 
1.7 (71% and 8%, respectively); our study accomplished similar seroconversion rates to that 
described by Svac. et al (73% with a Kt/V greater than 1.7 and 0% with a Kt/V below 1.7), but 
failed to reveal a statistically significant difference between groups, possibly reflecting the fact 
that only two patients had low PD adequacy. 
We did not find any studies evaluating seroconversion rate according to PET classification; 
our results show no statistical difference between high and low transporters (p = 0.580).     
Previous work (3) has shown a significant sex bias in seroconversion after HBV vaccine in 
HD patients, but not in PD patients. Identically, we did not find any link between gender and 
immune response, likewise Khan et al. (5).   
Former researches linked obesity to an unsatisfactory HBV immunoprophylaxis, either in 
non-dialysis (25), or HD patients (11). Khan et al. (5), in their meta-analysis, did not observe a 
significant weight difference between PD responders and non-responders. Accordingly, our 
results suggest that neither weight, nor BMI have an effect on seroconversion after HBV 
vaccine (p = 0.929 and p = 0.309, respectively), despite a larger proportion of responders 
among patients with a BMI below 25 kg/m
2
 (83% vs. 61%). 
Serum albumin levels have previously been reported to positively influence immune 
reactivity to HBV vaccine in HD (16) patients. As a matter of fact, Kara et al. (26) stated that 
failure to reach protective anti-HBs titres was significantly more frequent (87.5%) among HD 
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patients who had albumin levels between 3 and 3.5 g/dL, compared to albumin levels of at least 
4.5 g/dL. However, this was not the case in our study, which is in line with former data (27, 28). 
Smoking has been shown to suppress the immune system in CKD patients (29) and to 
adversely affect antibody formation upon hepatitis B vaccination (30). Still, in the present study, 
smoking status had no influence on immune response to HBV vaccine. 
Contradicting our results, HBV vaccine was found to be weakly immunogenic in renal 
transplant recipients by previous studies (18).  Such disparity may be due to extremely different 
sample sizes, since our study only comprised three transplant recipients. Moreover, comparing 
converters to non-converters, there was no difference concerning immunosuppressive therapy, 
which is in agreement with Khan et al. (5)  
In the current study, previous blood transfusions, haemoglobin levels and rHuEPO therapy 
did not predict response to HBV vaccination. Nevertheless, Bender et al. (31) showed that 
transfused patients on HD exhibit decreased absolute lymphocyte counts; still, most changes in 
T lymphocyte subsets happen beyond five transfusions (31) and we just evaluated blood 
transfusion as a dichotomous variable. In regard to the effect of both haemoglobin levels and 
rHuEPO therapy, literature is controversial: Al Saran et al. (32) did not find any link between 
haemoglobin levels and immunization, however Hassan et al. (1) mentioned a better immune 
response to HBV vaccine in CKD and HD patients with haemoglobin levels higher than 11 
gr/dL, perhaps translating higher EPO levels; indeed, some authors suggested that EPO might 
enhance B cell immunoglobulin production and proliferation (33) and directly improve immune 
reactivity among dialysis patients (17), but a meta-analysis (34) did not show an association 
between immune response to HBV vaccine and rHuEPO therapy in patients on dialysis, which 
mimics our results. 
Concerning dialysis modality, a robust analysis (6) showed no link between dialysis mode 
(either PD, or HD) and seroresponse rate to HBV vaccine, but we couldn’t find any studies 
comparing CAPD with APD in relation to the effectiveness of HBV immunoprophylaxis. Our 
findings suggest a greater response rate among APD users (86% vs. 57%), but this difference 
was not significant (p = 0.137), perhaps encouraging further studies with larger sample sizes. 
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The impact of RRF on HBV immunization has already been addressed (35) with similar 
results, that is, no difference between responders and non-responders.  
 According to previous work (36), peritonitis rate does not differ among responders and non-
responders to HBV vaccine (0.46/year and 0.33/year, respectively) and the present study also 
did not find any association between peritonitis burden and immune response. Nonetheless, it 
should be emphasized that only eight of our patients had peritonitis, none of them having more 
than two peritonitis episodes by the time of vaccination. 
Likewise Khan et al. (5), we did not observe any link between duration of PD prior to 
vaccination and seroconversion.  
In CKD patients, vitamin D deficiency is highly prevalent and negatively influences immune 
response to HBV vaccine (37). Notably, vitamin D receptors are widely expressed in immune 
system (38) and such vitamin has been linked with both innate and adaptive immune responses 
(39). However, a study comprising both HD and PD patients (39) showed that vitamin D levels 
are not significantly different among responders and non-responders to HBV vaccine. Once we 
didn´t have serum vitamin D measurements, we decided to compare vitamin D administration in 
seroconverters and non-converters. Vitamin D intake was not significantly different between 
both groups in the current study, which seems to agree with results provided by Jhorawat et al.  
(39). 
Afsar et al. (19) reported a significant negative association between depression and anti-HBs 
titres in HD patients. This has been partially attributed to an immunological dysregulation, 
mainly affecting the number and function of monocytes/macrophages and lymphocytes (40). In 
the present study, once again we considered need for antidepressant therapy as a marker of 
depression. Seroconversion rate was much lower among antidepressant users than non-users 
(33% vs. 72%, respectively), but such discrepancy was not statistically significant; however, 
one must be cautious when interpreting these results, since there were only three antidepressant 
users in our PD sample. 
Some limitations of our study must be addressed. First, our research is a retrospective study 
with its inherent disadvantages, namely certain unclear exposure status, lack of pertinent 
10 
 
medical records and impossibility to infer causality between older age and weakened immune 
response. Second, the small size of the PD sample precluded appliance of parametric tests and 
comparison of seroconversion rates between groups V1 and V2; still, our sample is made of 35 
patients, which is line with previous analysis performed with 40 PD patients by Svac et al. (24) 
and 32 patients by Dacko & Holley (35). Third, our findings need further validation using a 
multivariate model to adjust for potential confounding variables.  
The exclusive enrolment of PD patients and the assessment of seroconversion rate in an APD 
population are strengths of this study. We also would like to highlight the attempt to find an 
association between PET classification and seroconversion to HBV vaccination. 
 
 
CONCLUSIONS 
 
In conclusion, the present results highlight a significant association between older age and an 
impaired immune response to HBV vaccine among ESRD patients on maintenance PD. Further 
research with larger PD samples is needed to more accurately assess which other factors might 
be associated with HBV immunization. 
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TABLE 1 
 Peritoneal dialysis patients’ description  
Characteristic PD patients (n = 35) 
Age, yr 54 (45-65) 
≤50, n  14 (40.0%) 
>50, n  21 (60.0%) 
Gender  
Male, n 18 (51.4%) 
Female, n 17 (48.6%) 
Weight, kg 68.4 (62.3-68.7) 
BMI, kg/m
2
 27 (22-30) 
Smoking, n 9 (25.7%) 
Diabetes, n 8 (22.9%) 
Blood transfusion, n 13 (37.1%) 
CKD etiology  
ADPKD, n 1 (2.9%) 
Amyloidosis, n 1 (2.9%) 
CAF, n 2 (5.7%) 
CGN, n 5 (14.3%) 
Diabetes, n 6 (17.1%) 
Hypertension, n 7 (20.0%) 
Obstructive uropathy, n 2 (5.7%) 
Undetermined, n 11 (31.4%) 
Renal transplant, n 3 (8.6%) 
Time on PD pre-vaccination, months 2 (1-13) 
PD modality   
APD, n 14 (40.0%) 
CAPD, n 21 (60.0%) 
PD adequacy, Kt/V 2.3 (1.8-2.7) 
PET classification  
Low to low-average, n 4 (11.8%) 
High-average to high, n 30 (88.2%) 
RRF, mL/min 5.36 (3.86-8.67) 
Peritonitis 0 (0-1) 
Haemoglobin, g/dL  
Before vaccination 11.9 (10.8-12.6) 
After vaccination 11.4 (10.4-12.4) 
Albumin, g/L 
Before vaccination 
One year after vaccination 
 
39.1 (35.6-41.3) 
38.6 (35.3-41.0) 
On rHuEPO, n 20 (57.1%) 
On IST, n 3 (8.6%) 
On vitamin D, n 18 (51.4%) 
On antidepressants, n 3 (8.6%) 
Responders, n 24 (68.6%) 
Data are expressed as median (IQR) or n (%). 
BMI = body mass index; CKD = chronic kidney disease; ADPKD = 
autosomal dominant polycystic kidney disease; CAF = chronic allograft 
failure; CGN = chronic glomerulonephritis; PD = peritoneal dialysis; 
APD = automated PD; CAPD = continuous ambulatory PD; PET = 
peritoneal equilibration test; rHuEPO = recombinant human 
erythropoietin; IST = immunosuppressant therapy. 
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TABLE 2 
Comparison of Responders and Non-responders – numerical variables 
Characteristic 
Responders 
(n = 24) 
Non-responders 
(n = 11) 
p Value 
Age, yr 50 (43-56) 60 (54-68) 0.014 
Weight, kg 68.6 (62.3-78.6) 65 (62.3-79.3) 0.929 
BMI, kg/m
2
 26 (22-29) 27 (24-32) 0.309 
Time on PD pre-vaccination, months 4 (1-14) 1 (0-13) 0.367 
PD adequacy, Kt/V 2.3 (1.8-2.8) 2.3 (2.0-2.6) 0.669 
RRF, mL/min 5.45 (3.76-7.98) 4.98 (3.86-10.72) 0.644 
Peritonitis 0 (0-1) 0 (0-0) 0.302 
Haemoglobin, g/dL    
Before vaccination 11.7 (10.8-12.6) 12.0 (11.0-13-0) 0.581 
One year after vaccination 11.5 (10.5-12.6) 11.3 (10.4-11.9) 0.892 
Albumin, g/L    
Before vaccination 38.8 (36.6-41.2) 39.6 (34.7-41.3) 0.817 
One year after vaccination 38.4 (36.2-41.0) 40.4 (35.3-41.0) 0.931 
Data are expressed as median (IQR). 
BMI = body mass index; PD = peritoneal dialysis; RRF = residual renal function. 
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TABLE 3  
Comparison of Responders and Non-responders – categorical variables 
Characteristic 
Responders 
(n = 24) 
Non-responders 
(n = 11) 
p Value 
Age, yr   0.023 
≤50  13 (92.9) 1 (7.1) 
 
>50  11 (52.4) 10 (47.6) 
Gender   0.632 
Male  13 (72.2) 5 (27.8) 
 
Female 11 (64.7) 6 (35.3) 
BMI, kg/m
2
   0.259 
<25  10 (83.3) 2 (16.7) 
 
≥25  14 (60.9) 9 (39.1) 
Smoking 17 (70.8) 7 (29.2) 0.685 
Diabetes 3 (37.5) 5 (62.5) 0.077 
Blood transfusion 9 (69.2) 4 (30.8) 1.000 
Renal transplant 3 (100) 0 (0) 0.536 
PD modality   0.137 
APD  12 (85.7) 2 (14.3) 
 
CAPD 12 (57.1) 9 (42.9) 
PD adequacy, Kt/V   0.092 
<1.7 0 (0) 2 (100) 
 
≥1.7 24 (72.7) 9 (27.3) 
PET classification   0.580 
Low to low-average  2 (50) 2 (50) 
 
High-average to high 21 (70) 9 (30) 
Haemoglobin, g/dL    
Before vaccination   0.861 
<10 2 (66.7) 1 (33.3) 
 10-12 14 (73.7) 5 (26.3) 
>12 8 (61.5) 5 (38.5) 
One year after vaccination   0.434 
<10 4 (80.0) 1 (20.0)  
10-12 8 (57.1) 6 (42.9)  
>12 9 (81.8) 2 (18.2)  
On rHuEPO 13 (65.0) 7 (35.0) 0.721 
On IST 3 (100) 0 (0) 0.536 
On vitamin D 11 (61.1) 7 (38.9) 0.328 
On antidepressants 1 (33.3) 2 (66.7) 0.227 
Data are expressed as n (%). A 2-tailed value of p < 0.05 was considered significant.   
BMI = body mass index; PD = peritoneal dialysis; APD = automated PD; CAPD = continuous 
ambulatory PD; PET = peritoneal equilibration test; rHuEPO = recombinant human 
erythropoietin; IST = immunosuppressant therapy. 
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Figure 1 – Age and Seroconversion rate to hepatitis B vaccination.  
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Figure 2 – Age and hepatitis B surface antibody (Anti-HBs) titre after vaccination.  
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more	than	250	words,	with	the	following	subheadings:
•		 Background
•		 Methods
•		 Results
•		 Conclusions	(or	Summary)
For	Review	Articles,	Consensus	Statements,	Guidelines,	and	
Short	Reports,	 include	an	unstructured	abstract	of	no	more	
than	250	words	that	summarizes	the	objective,	main	points,	
and conclusions of the article. 
Do not include abstracts for Editorials, Commentaries, and 
Correspondence. 
After the abstract, list up to eight key words or phrases 
for	 indexing.	The	key	words	should	be	different	 from	those	
used	in	the	title.	A	list	of	key	words	is	required	for	all	Original	
Articles,	Review	Articles,	Consensus	Statements,	Guidelines,	
and	Short	Reports.	Key	words	are	optional	for	Correspondence;	
Commentaries do not have key words. Present the key words in 
one paragraph, separated by semi-colons, with a period at the 
end. Only the first key word should be capitalized.
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TEXT
Abbreviations and Symbols: Use	abbreviations	sparingly	and	
keep to those commonly used in the field. All acronyms and 
initialisms are to be spelled out on first use in the abstract, the 
text,	and	in	each	table	or	figure,	with	the	abbreviation	follow-
ing in parentheses. If the term is repeated less than four times 
in	the	text,	all	instances	must	be	spelled	out.	Abbreviations	
used in the body of the article should be indicated in the 
abstract, tables, and figures, even if they are used only once 
or twice in these sections, spelling out the first instance. 
Do not begin a sentence with an abbreviation. Spell the 
phrase	out	 in	 full	 or	 rewrite	 the	 sentence.	Do	not	explain	
abbreviations	for	units	of	measurement	[3	mL,	not	3	milliliters	
(mL)]	or	standard	scientific	symbols	[Na,	not	sodium	(Na)].	Do	
abbreviate long names of chemical substances and terms for 
therapeutic	combinations,	such	as	DNA.	Abbreviate	names	of	
tests and procedures that are better known by their abbrevia-
tions	than	by	the	full	name	(VDRL	test,	SMA-12).	Abbreviate	
units of measurement when they appear with numerals (mea-
sured	in	milliliters,	but	10	mL).	Use	abbreviations	in	figures	
and	tables	to	save	space.	Explain	all	abbreviations	used	in	the	
figure legend or table footnote. 
Units of Measurement: Use	SI	units	throughout.	When	units	
other than SI units are widely used, they can be indicated in 
parentheses after the SI unit. The editorial office will provide 
conversion information with the article when appropriate. 
Proprietary and Generic Names: Generic	names	must	be	used	
for all drugs. Include the proprietary name in the following 
cases: if it is more commonly known than the generic name; 
to differentiate among drug forms; if a specific trade prepara-
tion was used in a study or involved in an adverse effect. If the 
proprietary name is used, the name and location of the manu-
facturer	must	be	given	in	parentheses	in	the	text.	Instruments	
may be referred to by proprietary name; the name and location 
of	the	manufacturers	must	be	given	in	parentheses	in	the	text.	
Use of English Language: All papers are published in English, 
and authors who are not fluent in English are advised to seek 
editorial help before submitting their papers. This will help to 
ensure that the academic content of the paper is fully under-
stood by the journal editors and reviewers.
Organization: Organize	the	text	using	the	applicable	struc-
ture from the list set out here.
Original Articles: Introduction,	Methods,	Results,	Discussion,	
Conclusions, Acknowledgments (optional), Disclosures, 
References,	Figure	Legends,	and	Tables.	Additional	descriptive	
subheadings may be used if appropriate.
Review Articles: Introduction,	 Text	 (may	 include	Results	
and Discussion), Conclusions or Summary, Acknowledgments 
(optional),	Disclosures,	and	References.	
Short Reports: Introduction,	Materials	 and	Methods	or	
Case	Report,	 Results	 (omit	 for	 Case	Reports),	Discussion,	
Acknowledgments	 (optional),	References,	 Figure	 Legends,	
and Tables. Authors may insert a short summary/conclusion 
section following the discussion section if they wish. In some 
cases, results and discussions sections may more appropriately 
be combined than separated (at the author’s discretion).
Correspondence: Letters	dealing	with	published	articles	or	
matters of interest to researchers are invited. They should be 
short	(no	more	400	words,	1	 figure,	1	 table,	4	 references).	
Where	a	published	article	is	involved,	the	original	author(s)	
will be invited to submit a response.
REFERENCES
References	in	the	text	are	numbered	consecutively	using	Arabic	
numerals in parentheses. The manuscript’s reference list is 
numbered consecutively, using Arabic numerals, in the order 
in	which	the	references	are	 first	cited	 in	the	text.	Citations	
appearing in tables and figures must fit into the number-
ing	sequence	 from	the	point	at	which	the	 table	or	 figure	 is	
first	mentioned	 in	 the	 text.	PDI’s	citation	style	 follows	 the	
Vancouver style, which should be selected if using reference 
handling	software,	such	as	EndNote.	
 
Do: 
1. number references in the order in which they are first cited 
in	the	text;
2.	 use	Arabic	numerals	in	parentheses;
3.	 use	the	reference	style	of	the	National	Library	of	Medicine,	
including the abbreviations of journal titles, which should be 
abbreviated according to the style used in the list of Journals 
Indexed	for	MEDLINE,	posted	by	the	NLM	on	the	Library’s	Web	
site (http://www.nlm.nih.gov/tsd/serials/lji.html);
4.	 include	an	“available	from”	note	for	documents	that	may	
not be readily accessible;
5.	 cite	symposium	papers	only	from	published	proceedings;
6. when citing an article or book accepted for publication but 
not yet published, include the title of the journal (or name 
of	the	publisher)	and	the	year	of	expected	publication;	
7.	 when	citing	an	article	that	has	been	published	online	but	not	
yet in print, include the digital object identifier (doi); and
8.	 include	references	to	unpublished	material	in	the	text,	not	
in	the	references	[for	example,	papers	presented	orally	at	
a meeting; unpublished work (personal communications, 
papers in preparation)] and submit a letter of permission 
from the cited persons to cite such communications. 
Do not use ibid. or op cit.
Sample References: The sample references below are based 
on	the	style	specified	by	the	Uniform	Requirements	agreement.
Journals: List	all	authors	when	six	or	fewer;	when	seven	or	
more,	list	only	the	first	six	and	add	et al. (in italics).
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Standard article
 Vega	KJ,	Pina	I,	Krevsky	B.	Heart	transplantation	is	associ-
ated with an increased risk for pancreatobiliary disease. Ann 
Intern Med	1996;	124:980–3.
	Haag-Weber	M,	Kramer	R,	Haake	R,	Islam	MS,	Prischl	F,	Haug	
U,	et al. Low-GDP	fluid	(Gambrosol	trio)	attenuates	decline	
of residual renal function in PD patients: a prospective ran-
domized study. Nephrol Dial Transplant	2010;	25:2288–96.
Corporate author
 The	Cardiac	Society	of	Australia	and	New	Zealand.	Clinical	
exercise	stress	testing.	Safety	and	performance	guidelines.	
Med J Aust	1996;	164:282–4.
Supplement
 Shen	HM,	Zhang	QF.	Risk	assessment	of	nickel	carcinogenic-
ity	and	occupational	lung	cancer.	Environ	Health	Perspect 
1994;	102(Suppl	1):275–82.
Special format (also applies to abstracts and editorials) 
 Enzensberger	W,	 Fischer	 PA.	Metronome	 in	Parkinson’s	
disease	[Letter].	Lancet	1996;	347:1337.	
Books: List	all	authors	or	editors	when	six	or	fewer;	when	 
seven	or	more,	list	only	the	first	six	and	add	et al. (in italics).
Author
	Ringsven	MK,	Bond	D.	Gerontology and leadership skills for 
nurses.	2nd	ed.	Albany,	NY:	Delmar;	1996.
Editors
	Norman	IJ,	Redfern	SJ,	eds.	Mental Health Care for Elderly 
People.	New	York,	NY:	Churchill	Livingstone;	1996.
Chapter in a book
	Phillips	 SJ,	Whisnant	 JP.	Hypertension	 and	 stroke.	 In:	
Laragh	JH,	Brenner	BM,	eds.	Hypertension: Pathophysiology, 
Diagnosis, and Management.	2nd	ed.	New	York,	NY:	Raven	
Press;	1995:	465–78.
Published proceedings paper
	Bengtsson	S,	Solheim	BG.	 Enforcement	of	data	protec-
tion,	privacy	and	security	in	medical	informatics.	In:	Lun	
KC,	Degoulet	 P,	 Piemme	 TE,	 Rienhoff	O,	 eds.	MEDINFO	
92.	 Proceedings	 of	 the	7th	World	 Congress	 on	Medical	
Informatics;	6–10	September	1992;	Geneva,	Switzerland.	
Amsterdam:	North-Holland;	1992:	1561–5.	
Other Citations in Reference List
In press (must have journal title) 
 Leshner	AI.	Molecular	mechanisms	of	 cocaine	addiction.	 
N Engl J Med 1996; [In press].
Publish­ahead­of­print
 Smith J. Important science breakthrough. J Thght	2009;	
Epub	ahead	of	print.	doi:	10.1186/s12906-015-0739-8
Magazine article
Roberts	JL.	Villain	or	victim?	Newsweek.	1996;	4	Nov:40–1.	
In-Text Citations of Unpublished Material
(to be placed within parentheses)
Personal communication
(Strott	CA,	Nugent	CA.	Personal	communication).
Unpublished papers
	(Lerner	RA,	Dixon	FJ.	The	induction	of	acute	glomerulone-
phritis in rats. In preparation.) 
	(Smith	J.	New	agents	for	cancer	chemotherapy.	Presented	
at	the	Third	Annual	Meeting	of	the	American	Cancer	Society,	
13	June	1983,	New	York,	NY)	
TABLES
Authors are asked to keep each table to a reasonable size; 
very large tables packed with data simply confuse the reader 
and	may	be	included	as	Supplemental	Material	(see	below).	
Similarly, try to minimize the use of abbreviations, and if 
abbreviations must be used, use well-known and accepted 
forms to minimize the need for the reader to constantly refer 
to the table legend. The same data should not be presented 
in both a table and a figure.
Tables are to be numbered using Arabic numerals in the order 
in	which	they	are	cited	in	the	article	text.	Tables	should	also	
have a title (above the table) that summarizes the whole table; 
it	should	be	no	longer	than	15	words.	Every	table	column	and	
row	should	be	provided	with	an	explanatory	title	stub,	with	units	
of measure applicable to the row or column clearly indicated.
Tables must be formatted using the table tool in a word 
processing program to ensure that columns of data remain 
aligned when the file is sent electronically for review. The table 
should be formatted with a horizontal line above the column 
title stubs, between the column title stubs and the table body, 
and at the end of the table body. Vertical lines, color, and shad-
ing are not to be used; parts of the table can be highlighted 
using	symbols	or	bold	text,	the	meaning	of	which	should	be	
explained	in	the	table	legend.	Tables	must	not	be	embedded	
as figures or spreadsheet files.
Table legends follow the table body and should be as concise 
as possible. Footnotes follow the table legend and should be 
indicated using superscripted lowercase letters (a, b, c, and 
so on). Tables (together with their footnotes and legends) 
should	be	completely	intelligible	without	reference	to	the	text.
All tables (including their associated title, footnotes, and 
legends) should appear in consecutive numerical order after 
the references and any figure legends. All tables will be placed 
close	to	their	text	citations	during	article	 layout.	All	 tables	
must	be	cited	in	the	article	text.
FIGURES
Format: Figures	for	reproduction	should	approximately	fit	
within the typeset area of the journal. The following resolu-
tions are optimal:
•		 Black-and-white	line	drawings,	600–1200	dpi
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•		 Line	drawings	with	some	grey	or	coloured	lines,	600	dpi
•		 Illustrations	and	photographs,	300	dpi
Authors should supply electronic versions of the figure 
content	in	EPS,	GIF,	TIFF,	or	JPEG	format.	Other	formats,	such	
PDFs, may be used, but are not preferred. Drawings made in 
Microsoft	Word	 and	PowerPoint	 are	discouraged,	 because	
the display of such drawings varies with the settings of each 
computer used to view the file. There is no guarantee that such 
figures	will	reproduce	exactly	as	intended	by	the	author.	Save	
each figure in a separate file without its title or legend, and 
use	simple	 file-naming	conventions	 (for	example,	Figure	1,	 
Figure	2A).	
Note About Color Figures: Please note that all figures are 
reproduced in black and white in the print version of the 
journal,	unless	color	 is	 requested	by	 the	authors.	Colors	 in	
a figure that are of different hue but similar intensity might 
not be distinguishable when reproduced in shades of grey. 
It is the author’s responsibility to ensure that colors used in 
figures are distinguishable when printed in black and white. 
Any figure that is to be printed in color should be specified by 
the author. There is no cost associated with color reproduction; 
however	figures	will	only	be	printed	in	color	when	required	for	
correct depiction. 
Submission: All figures should be individually uploaded in 
the online submission process. 
Figure Legends: Figures are to be numbered using Arabic 
numerals	(1,	2,	3,	and	so	on)	in	the	order	in	which	they	are	
cited	in	the	article	text.	If	a	figure	has	several	panels,	each	
panel should be identified using an uppercase alphabetic 
character	(A,	B,	C,	and	so	on).	Each	figure	should	have	a	title	
and	an	explanatory	legend	that	clearly	identifies	the	mean-
ing of any symbols, arrows, numbers, or abbreviations used 
in the illustration. The legend should permit the figure to be 
understood	without	reference	to	the	text.
Title and legend information for each figure should be 
included	with	the	article	text,	grouped	and	placed	at	the	end	
of the manuscript, after the reference list. All figures will be 
placed	close	to	their	text	citations	during	article	layout.	Make	
sure	that	each	figure	is	cited	in	the	article	text.
SUPPLEMENTAL	MATERIAL
Authors may submit supplemental material to accompany 
their article for online-only publication when there is insuf-
ficient space to include the material in the print article. 
The material will be posted on the journal’s website with 
the article, and may consist of data files, graphics, video or 
extensive	 tables.	 This	material	 should	be	 important	 to	 the	
understanding and interpretation of the report and should 
not repeat material in the print article. The amount of supple-
mental material should be limited and justified. The printed 
article	must	be	complete	and	self-explanatory	without	 the	
supplemental material. The material is intended to enhance 
a reader’s understanding of the paper, but is not essential to 
that understanding. The material should be original and not 
previously published.
How to Supply Supplemental Material: Supplemental 
material will undergo editorial and peer review with the main 
manuscript. If the manuscript is accepted for publication and 
if the material is deemed appropriate for publication by the 
editors, it will be posted online at the time of publication of 
the article as additional material provided by the authors. This 
material will not be edited or formatted; thus, authors are 
responsible for the accuracy and presentation of all such mate-
rial. Files cannot be altered, nor new supplemental information 
added, after the paper has been accepted for publication unless 
requested	by	the	Editorial	Office.
Supplemental	material,	with	 the	exception	of	audio	and	
video,	 should	 be	 submitted	 in	 a	 single	Word	 document.	
The first page of the document must be the journal’s stan-
dard cover page, which can be downloaded from https://
mc.manuscriptcentral.com/societyimages/peritdialint/
Supplemental%20Materials%20Template_2015.docx	 .	 The	
cover page should include the article title, authors, listing 
of supplemental files and corresponding author informa-
tion. Each element included in the material should be 
cited	 in	the	text	of	the	main	manuscript	(eg.	Supplemental	
Figure	 1)	 and	 numbered	 in	 order	 of	 citation	 in	 the	 text	 
(eg.	Supplemental	Table	1,	Supplemental	Table	2,	Supplemental	
Figure 1). Supplemental material should be uploaded with 
your manuscript.
Formatting	requirements	for	each	supplemental	material	
type are outlined below:
Supplemental Text: Supplemental	text	should	be	set	in	Times	
New	Roman	font,	10	point	in	size,	and	single-spaced.	The	main	
heading	of	 the	online-only	 text	 should	be	 in	12	point	and	
boldface; subheadings should be in 10 point and boldface. 
References: All references cited within the supplemental 
document must be included in a separate reference section, 
including those that also were cited in the main manuscript. 
They should be formatted just as in the main manuscript 
and numbered and cited consecutively in the supplemen- 
tal material.
Supplemental Tables: Supplemental tables should be inserted 
in the document and numbered consecutively according to 
the order of citation as Supplemental Table 1, Supplemental 
Table	2,	etc.	See	also	instructions	for	tables	above.	If	a	table	
runs	on	to	subsequent	pages,	repeat	the	column	headers	at	
the	top	of	each	page.	Wide	tables	may	be	presented	using	a	
landscape orientation.
Supplemental Figures: Supplemental f igures should be 
 inserted in the document and numbered consecutively according 
to the order of citation as Supplemental Figure 1, Supplemental 
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Figure	2,	etc.	See	also	 instructions	 for	 figures	above.	Wide	
figures may be presented using a landscape orientation.
Video: Submit videos according to the following specifications:
•		 Acceptable	file	formats:	.mov,	.wmv,	.mpg,	.mpeg,	.mp4,	or	.avi
•		 Maximum	file	size:	10	MB
•		 Maximum	length:	1	minute
Verify	that	the	videos	are	viewable	in	QuickTime	or	Windows	
Media	Player.
Authors	will	be	notified	 if	problems	exist	with	videos	as	
submitted	and	will	be	asked	to	modify	them.	No	editing	will	
be done to the videos at the editorial office. All changes are 
the responsibility of the author.
File name(s) should be one word with no spaces and the 
appropriate	extension	at	the	end.	(eg.	Video1.mov)
For each video, provide a citation in the appropriate place in 
the	manuscript	text	and	include	a	title	(a	brief	phrase,	prefer-
ably	no	longer	than	10	to	15	words)	and	a	caption	at	the	end	
of the manuscript. In the video caption, specify the video file 
format and briefly describe the content of the video. If multiple 
video files are submitted, number them in the order in which 
they should be viewed.
If the author does not hold copyright to the video, the 
author must obtain permission for the video to be published in 
PDI. This permission must be for unrestricted use in all print, 
online, and licensed versions of PDI.
Audio: Please submit audio files according to the following 
minimum	requirements:
•		 Acceptable	file	formats:	.mp3,	.wav,	or	.aiff
•		 Maximum	file	size:	10	MB
•		 To	achieve	 the	best	quality,	when	 saving	audio	 files	 as	
an	mp3,	use	a	setting	of	256	kbps	or	higher	for	stereo	or	
128 kbps	or	higher	for	mono
•		 Sampling	rate	should	be	either	44.1	kHz	or	48	kHz
•		 Bit	rate	should	be	either	16	or	24	bit
For each audio, provide a citation in the appropriate place 
in	the	manuscript	text.	Ensure	the	audio	is	briefly	described	
within	the	text	(preferably	no	longer	than	10	to	15	words).		
File name(s) should be one word with no spaces and the 
appropriate	extension	at	the	end.	(eg.	Audio1.mp3).
Supplemental Material Fees: The author will be charged a 
fee	of	$50.00	US	per	file,	which	will	be	invoiced	upon	article	
acceptance.	Payment	must	be	made	within	30	days.	
PERMISSIONS
Please note it is the responsibility of the author(s) to 
obtain permission from the copyright holder to reproduce 
figures or tables that have previously been published else-
where. This includes a full bibliographic reference to the 
original publication and an acknowledgement that the 
material is reproduced with permission from the rights 
owner within the legend. Authors are responsible for any 
permission	 fees	 requested	 by	 the	 copyright	 holder.	 The	
permission letter or proof should be supplied by the author 
along with their copyright transfer agreement or license 
to publish. 
REPORTING	GUIDELINES
Clinical Trials: The	 ICMJE	defines	 a	 clinical	 trial	 as	 any	
research project that prospectively assigns human participants 
to intervention or comparison groups to study the cause-
and-effect relationship between an intervention and a health 
outcome.	PDI	requires	that	all	trials	be	registered	and	supports	
the position of the AllTrials.net Initiative in that we may still 
consider	 retrospectively	 registered	 trials	 if	 the	exceptional	
circumstances	of	non-prospective	registration	are	explained	
with a statement included in the methods section.  For all trials, 
authors are asked to provide the trial registration information 
from an approved registry. 
Authors of randomized trials are encouraged to adhere 
to	CONSORT	guidelines	appropriate	to	their	trial	design.	The	
manuscript	 should	 include	 a	 CONSORT	 flow	diagram.	 The	
CONSORT	checklist	should	be	completed	and	submitted	with	
the manuscript as a supporting file. To help ensure the study 
is	appropriately	indexed,	authors	should	use	the	word	“ran-
domized”	in	the	title.	Authors	must	explicitly	discuss	informed	
consent	in	the	manuscript	and	PDI	reserves	the	right	to	request	
further details.
Observational Studies: Observational studies including 
case control, cohort, and cross-sectional studies. Authors are 
encouraged to adhere to the STROBE	Statement	and	include	a	
completed checklist as a supporting file. 
Systematic Reviews and Meta-Analyses: Reports	of	system-
atic reviews and meta-analyses should adhere to the PRISMA	
Statement or alternative guidelines appropriate to the study 
design, and include the flow diagram within the manuscript 
and the completed checklist as a supporting file. 
Diagnostic Studies: Authors of studies of diagnostic accu-
racy are encouraged to adhere to the STARD	requirements	or	
alternative guidelines appropriate to the study design and 
include a completed checklist as a supporting file. 
Animal Studies: Authors of studies including animals are 
encouraged	to	adhere	to	the	ARRIVE	guidelines	and	include	a	
completed	ARRIVE	checklist	as	a	supporting	file.
Survey Research: Manuscripts	reporting	survey	data	should	
use data collected as recently as possible, ideally within the 
past	2	years.	Surveys	should	have	sufficient	response	rates	to	
ensure that nonresponse bias does not threaten the validity 
of the findings. In addition, authors should submit the survey 
instrument itself which might be published as an online-only 
supplemental file.
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SUBMISSION	OF	PAPERS
All manuscripts must be submitted online at https://
mc.manuscriptcentral.com/peritdialint. If visiting from 
www.pdiconnect.com,	click	on	“Submit	to	PDI”.	Type	your	exist-
ing	login/password,	or	click	on	“Create	an	account”.	Be	careful	
not to create more than one account for yourself. The same 
account will be used whether you are submitting or reviewing 
a manuscript. You can make changes to your account at any 
time, once you are logged in. Once logged in you will also have 
access to different centers. To submit your manuscript, click 
on	“Author	Center”	and	follow	the	instructions.	If	you	require	
assistance	during	the	submission	process,	click	on	“Get	Help	
Now”	in	the	upper	right	hand	corner.	
Additional resources for online submissions assistance:
•		 Scholarone	manuscripts	–	Author	Guide	(http://mchelp.
manuscriptcentral.com/gethelpnow/training/author) 
All components of the manuscript must appear within a 
single	Microsoft	Word	document	file.	References,	figure	leg-
ends, and tables are to appear at the end of the manuscript. 
Figures and supplemental files are to be uploaded as separate 
files during the online submission process. 
At	time	of	submission,	we	request	that	the	authors	provide	
at least three potential reviewers. These reviewers should not 
have published with any of the co-authors during the past five 
years and should not currently work or collaborate with one of 
the institutes of the co-authors of the submitted manuscript.
REVISIONS	OF	PAPERS
When	you	prepare	a	revised	version	of	your	manuscript,	it	
is essential that you carefully follow the instructions given in 
the Editor’s email regarding preparation of the same. Failure 
to do so will cause a delay in the review of your revision and 
may result in return of the revision to you, without review, for 
proper	preparation.	If	a	revision	is	not	received	within	3	months	
after	requested,	your	file	may	be	closed.	
PROOFS AND PUBLICATION
COPYEDITING
After final acceptance of your manuscript, it will be copy-
edited before publication to conform to Peritoneal Dialysis 
International’s style and usage. This editing may be substan-
tive. It is the responsibility of the corresponding author to 
read the copyedited manuscript he or she will receive and to 
answer	all	queries	fully.
PROOFREADING
The corresponding author will receive an email with the PDF 
file of the proof. The email includes instructions for correcting 
and	returning	the	proof	using	Adobe	Reader.	If	using	the	PDF	
annotations function is not feasible, corrections can be listed 
with corresponding page, paragraph and line number and 
returned	via	email.	Please	return	the	proof	within	72	hours.	You	
will not receive second proofs, so it is important to ensure that 
all	necessary	corrections	are	made	any	queries	are	answered.	
Authors	should	take	extra	care	to	ensure	that	all	author	details	
and affiliations are correct and complete.
COPYRIGHT
Authors submitting manuscripts to Peritoneal Dialysis 
International do so with the understanding that if a manu-
script is accepted, the copyright of the article, including the 
right to reproduce the article in all forms and media, shall be 
assigned	exclusively	to	the	International	Society	for	Peritoneal	
Dialysis.	The	corresponding	author	will	be	required	to	sign	a	
“Copyright Transfer Agreement” on behalf of all authors. This 
must be completed and returned to the Editorial office before 
an accepted article can be published in the journal. PDI allows 
authors	 to	 retain	a	number	of	nonexclusive	 rights	 to	 their	
published article. See the “Copyright Transfer Agreement” or 
“Author	Rights”	for	details.
Authors of accepted manuscripts may choose to pay an 
article processing fee in order for their article to be published 
open access, where articles are made freely available upon 
publication. See “Open Access Option for Authors”.
AUTHOR RIGHTS
As an author, you are granted specific rights for a large 
number of author uses, which are granted and permitted with-
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